Rocuronium bromide injection

Component:
Rocuronium Bromide 5ml:50mg

Character:
This product is colorless to yellowish clear liquid.

Indications:

Rocuronium bromide is used as an adjunct to general anesthesia for tracheal intubation during routine induction of anesthesia and for maintaining intraoperative skeletal muscle relaxation.

Usage and dosage:

As with other muscle relaxants, the dosage of rocuronium bromide should be individualized. The following factors should be given due consideration in determining the dosage:

Method of anesthesia, time of operation, method of sedation and time of mechanical ventilation, interaction of other drugs used at the same time, and patient condition, etc. Appropriate muscle release monitoring techniques are recommended to assess muscle release depth and recovery status.

Inhaled anesthetics do enhance the muscle release effect of rocuronium bromide, however, this synergistic effect is clinically significant only when inhaled anesthetics are present in tissue at the required concentration to produce the effect. Therefore, during prolonged surgery (more than 1 hour) under aspiration anesthesia, the maintenance dose of rocuronium bromide should be reduced, the time between administration should be prolonged, or the infusion rate should be slowed down.

Precautions:

Allergic reactions may occur after use of neuromuscular blockers. Precautions should always be taken against such reactions. Because cross-allergic reactions between neuromuscular blockers have been reported, special precautions should be taken, especially in patients who have previously had an allergic reaction to other neuromuscular blockers.

Neuromuscular drugs are known to induce histamine release at the injection site and throughout the body. Therefore, always be aware of the possibility of pruritus and erythema at the injection site and/or systemic histamine-like (allergic) reactions when using these drugs. Clinical studies have shown a slight increase in mean plasma histamine hydropine after rapid intravenous administration of rocuronium 0.3-0.9mg/kg.

Prolonged use of neuromuscular blockers is known to prolong paralysis and/or skeletal muscle weakness, usually in the intensive care unit (ICU). To help avoid possible prolonged neuromuscular hysteresis and/or overdose, it is strongly recommended that neuromuscular conduction be monitored throughout the administration of neuromuscular blockers. In addition, patients should receive appropriate analgesia and sedatives during the neuromuscular block. Furthermore, neuromuscular blockers should be dosed according to the individual patient by or under the guidance of an experienced clinician who is familiar with their effects and neuromuscular monitoring techniques.